Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
Johns Hopkins University · Johns Hopkins Medicine · +22 more institutions
Indexed incrossrefpubmed
Abstract
PURPOSE: We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic non-small-cell lung cancer, regardless of tumor programmed death ligand 1 (PD-L1) status. METHODS: alterations and with tumor PD-L1 ≥ 1% or
Citation impact
372
total citations
- FWCI
- 34.22
- Percentile
- 100%
- References
- 27
Citations per year
Authors
24- JRJulie R. BrahmerCorresponding
Johns Hopkins University, Johns Hopkins Medicine, Sidney Kimmel Cancer Center
- JLJong-Seok Lee
Seoul National University Bundang Hospital
- TCTudor–Eliade Ciuleanu
Institute of Oncology Prof. Dr. Ion Chiricuta, Sidney Kimmel Cancer Center
- RBReyes Bernabe Caro
Instituto de Biomedicina de Sevilla
- MNMakoto Nishio
Japanese Foundation For Cancer Research
Topics & keywords
Topics
Keywords
- Nivolumab
- Ipilimumab
- Medicine
- Internal medicine
- Oncology
- Lung cancer
- Chemotherapy
- Discontinuation
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- ATAgilent TechnologiesAward: PD-L1 IHC 28-8
- AAstraZeneca
- GGlaxoSmithKline
- SSanofi
- TPTeva Pharmaceutical Industries
- CCelgene
- TPTaiho Pharmaceutical
- MTMirati Therapeutics
- BBeiGene
- SServier
- PPharmaMar
- OPOno Pharmaceutical
- MMorphoSys
- IIpsen
- GGenentech
- PPharmacyclics
- DSDaiichi Sankyo Europe